These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 18482053)

  • 1. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
    Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
    Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.
    Gaikwad A; Prchal JT
    Exp Hematol; 2007 Nov; 35(11):1647-56. PubMed ID: 17976517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
    Quintás-Cardama A; Manshouri T; Estrov Z; Harris D; Zhang Y; Gaikwad A; Kantarjian HM; Verstovsek S
    Invest New Drugs; 2011 Oct; 29(5):818-26. PubMed ID: 20372971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
    Shi J; Yuan B; Hu W; Lodish H
    Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib effect on growth and signal transduction in polycythemia vera.
    Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
    Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
    Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
    Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
    Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
    Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
    PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
    Ueda F; Tago K; Tamura H; Funakoshi-Tago M
    J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
    Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O
    PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
    Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
    Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
    Scott LM; Tong W; Levine RL; Scott MA; Beer PA; Stratton MR; Futreal PA; Erber WN; McMullin MF; Harrison CN; Warren AJ; Gilliland DG; Lodish HF; Green AR
    N Engl J Med; 2007 Feb; 356(5):459-68. PubMed ID: 17267906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.
    Laubach JP; Fu P; Jiang X; Salter KH; Potti A; Arcasoy MO
    Exp Hematol; 2009 Dec; 37(12):1411-22. PubMed ID: 19815050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.
    Majumder A; Govindasamy L; Magis A; Kiss R; Polgár T; Baskin R; Allan RW; Agbandje-McKenna M; Reuther GW; Keseru GM; Bisht KS; Sayeski PP
    J Biol Chem; 2010 Oct; 285(41):31399-407. PubMed ID: 20667821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera.
    Tsuruta-Kishino T; Koya J; Kataoka K; Narukawa K; Sumitomo Y; Kobayashi H; Sato T; Kurokawa M
    Oncogene; 2017 Jun; 36(23):3300-3311. PubMed ID: 28068330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera.
    Ma AC; Fan A; Ward AC; Liongue C; Lewis RS; Cheng SH; Chan PK; Yip SF; Liang R; Leung AY
    Exp Hematol; 2009 Dec; 37(12):1379-1386.e4. PubMed ID: 19772888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
    Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
    Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
    Li Z; Xu M; Xing S; Ho WT; Ishii T; Li Q; Fu X; Zhao ZJ
    J Biol Chem; 2007 Feb; 282(6):3428-32. PubMed ID: 17178722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib inhibits progenitor cell proliferation from polycythaemia vera.
    Wappl M; Jaeger E; Streubel B; Gisslinger H; Schwarzinger I; Valent P; Oehler L
    Eur J Clin Invest; 2008 Aug; 38(8):578-84. PubMed ID: 18717827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.